&lt;p&gt;Aptamers as Versatile Ligands for Biomedical and Pharmaceutical Applications&lt;/p&gt;

Guan, Baozhang; Zhang, Qizhou

doi:10.2147/ijn.s237544

Cited by 80 publications

(42 citation statements)

References 90 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Aptamers are short RNAs or DNAs made up by 20-80 nucleotides. Aptamers can fold into unique three-dimensional conformations to specifically bind to targets (13). F79 synthetic peptide is a member of the aptamers that contains a sequence of 13 amino acids surrounding RAD52 (F79) (VINLANEMFGYNG-GGG-YARAAARQARA), and this was purchased from Genemed Synthesis Inc.. F79 has a three-residue polyglycine linker and protein transduction domain 4; these facilitate passage across lipid bilayers and direct intracellular transduction of the aptamers (14).…”

Section: Methodsmentioning

confidence: 99%

RAD52 aptamer regulates DNA damage repair and STAT3 in BRCA1/BRCA2‑deficient human acute myeloid leukemia

Lin

Luo

et al. 2020

Oncol Rep

View full text Add to dashboard Cite

RAD52 (Radiation sensitive 52) is a key factor in DNA damage repair (DDR) bypass, which participates in single-strand annealing (SSA) after DNA damage end excision, while breast cancer type 1 susceptibility protein (BRCA1)/breast cancer type 2 susceptibility protein (BRCA2) play critical roles in homologous recombination (HR) repair. The present study aimed to determine whether RAD52-induced regulation of repair bypass occurs in acute myeloid leukemia (AML) cells and to explore the underlying mechanism. Herein, we applied an RAD52 aptamer to AML cells with downregulated BRCA1/2. RAD52 aptamer inhibited AML cell proliferation detected by cell counting, promoted cell apoptosis obtained by flow cytometry, and suppressed DNA damage repair behavior measured by comet assay and flow cytometry, after drug intervention during low expression of BRCA1/2. During this process, DDR-related cell cycle checkpoint proteins were activated, and the cells were continuously arrested in the S/G2 phase, which affected the cell damage repair process. Concurrently, the expression levels of apoptosis-related proteins were also altered. Furthermore, the expression of STAT3 and p-STAT3 was downregulated by the RAD52 aptamer, suggesting that RAD52 affects the STAT3 signaling pathway. In summary, we present a possible role for RAD52 in DDR of BRCA1/2-deficient AML cells that involves the STAT3 signaling pathway.

show abstract

Section: Methodsmentioning

confidence: 99%

RAD52 aptamer regulates DNA damage repair and STAT3 in BRCA1/BRCA2‑deficient human acute myeloid leukemia

Lin

Luo

et al. 2020

Oncol Rep

View full text Add to dashboard Cite

show abstract

“…Another class of compound that can be used as a targeting agent are aptamers. They are defined as short RNA or single-stranded DNA oligonucleotides or oligopeptides (5–80 amino acids), which can bind to specific targets through folding into unique three-dimensional conformations [ 143 , 144 ]. Aptamers have unique characteristics such as small size, high stability, structure flexibility, ease of synthesis, and low or no immunogenicity, and these make them a great targeting agent [ 145 ].…”

Section: Msns As Smart Drug Delivery Agentmentioning

confidence: 99%

Progress in Mesoporous Silica Nanoparticles as Drug Delivery Agents for Cancer Treatment

et al. 2021

View full text Add to dashboard Cite

Cancer treatment and therapy have made significant leaps and bounds in these past decades. However, there are still cases where surgical removal is impossible, metastases are challenging, and chemotherapy and radiotherapy pose severe side effects. Therefore, a need to find more effective and specific treatments still exists. One way is through the utilization of drug delivery agents (DDA) based on nanomaterials. In 2001, mesoporous silica nanoparticles (MSNs) were first used as DDA and have gained considerable attention in this field. The popularity of MSNs is due to their unique properties such as tunable particle and pore size, high surface area and pore volume, easy functionalization and surface modification, high stability and their capability to efficiently entrap cargo molecules. This review describes the latest advancement of MSNs as DDA for cancer treatment. We focus on the fabrication of MSNs, the challenges in DDA development and how MSNs address the problems through the development of smart DDA using MSNs. Besides that, MSNs have also been applied as a multifunctional DDA where they can serve in both the diagnostic and treatment of cancer. Overall, we argue MSNs provide a bright future for both the diagnosis and treatment of cancer.

show abstract

“…This is the case of the drug pegaptanib, the first aptamer-based drug approved by the FDA, which binds and counteracts the action of VEGF in the treatment of age-related macular regeneration [ 90 , 91 , 92 ]. Importantly, as consequence of their small size and high tissue penetration, aptamers can also be used as delivery cargoes following conjugation with other drugs, such as proteins, small molecules or other oligonucleotides [ 4 , 86 , 93 , 94 , 95 ]. This option, together with high target specificity, represents a huge advantage in the use of oligonucleotide-based therapies, for which delivery problems and off-target effects are still among its main drawbacks precluding further development.…”

Section: Oligonucleotides Used In Therapeuticsmentioning

confidence: 99%

Oligonucleotide-Based Therapies for Renal Diseases

et al. 2021

View full text Add to dashboard Cite

The global burden of chronic kidney disease (CKD) is increasing every year and represents a great cost for public healthcare systems, as the majority of these diseases are progressive. Therefore, there is an urgent need to develop new therapies. Oligonucleotide-based drugs are emerging as novel and promising alternatives to traditional drugs. Their expansion corresponds with new knowledge regarding the molecular basis underlying CKD, and they are already showing encouraging preclinical results, with two candidates being evaluated in clinical trials. However, despite recent technological advances, efficient kidney delivery remains challenging, and the presence of off-targets and side-effects precludes development and translation to the clinic. In this review, we provide an overview of the various oligotherapeutic strategies used preclinically, emphasizing the most recent findings in the field, together with the different strategies employed to achieve proper kidney delivery. The use of different nanotechnological platforms, including nanocarriers, nanoparticles, viral vectors or aptamers, and their potential for the development of more specific and effective treatments is also outlined.

show abstract

<p>Aptamers as Versatile Ligands for Biomedical and Pharmaceutical Applications</p>

Cited by 80 publications

References 90 publications

RAD52 aptamer regulates DNA damage repair and STAT3 in BRCA1/BRCA2‑deficient human acute myeloid leukemia

RAD52 aptamer regulates DNA damage repair and STAT3 in BRCA1/BRCA2‑deficient human acute myeloid leukemia

Progress in Mesoporous Silica Nanoparticles as Drug Delivery Agents for Cancer Treatment

Oligonucleotide-Based Therapies for Renal Diseases

Contact Info

Product

Resources

About